Search

Displaying results 2531 - 2540 of 8575 in total
  1. Drug

    Menotropins

    go.drugbank.com/drugs/DB00032
    ApprovedInvestigational

    It is used as a fertility medication that is injected either subcutaneously or intramuscularly.

  2. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073].

  3. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP.

  4. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    [L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation

  5. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257].

  6. Drug

    Fendiline

    go.drugbank.com/drugs/DB08980
    ApprovedWithdrawn

    It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.

  7. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  8. Drug

    Berberine

    go.drugbank.com/drugs/DB04115
    ApprovedInvestigationalWithdrawn

    It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.

  9. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.

  10. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [L13338] The action of hyaluronidase was first described in 1936, and named in 1939. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]